Review
Oncology
Judd W. Moul, Neal D. Shore, Kenneth J. Pienta, Johannes Czernin, Martin T. King, Stephen J. Freedland
Summary: This narrative review examines the clinical evidence on the utility of next-generation imaging (NGI) for patients with biochemical recurrence (BCR) in prostate cancer. NGI technologies have demonstrated increased sensitivity and selectivity for diagnosing BCR, but limited clinical evidence exists on the application of NGI to treatment decision-making and patient outcomes.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Oncology
Nicholas Spetsieris, Myrto Boukovala, Ioannis Alafis, John Davis, Amado Zurita, Xuemei Wang, Shi-Ming Tu, Brian F. Chapin, Ana Aparicio, Paul Corn, Jennifer Wang, Sumit K. Subudhi, John Araujo, John Papadopoulos, Lisa Pruitt, Justin A. Weldon, Christopher J. Logothetis, Eleni Efstathiou
Summary: The study showed that finite-duration treatment with ADT and Abi + P in biochemically recurrent prostate cancer patients resulted in a significantly longer PSA relapse-free interval compared to ADT alone, without affecting the recovery time to eugonad state.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Biochemistry & Molecular Biology
Rie von Eyben, Manuela Andrea Hoffmann, Cigdem Soydal, Irene Virgolini, Murat Tuncel, Mathieu Gauthe, Daniel S. Kapp, Finn Edler von Eyben
Summary: A biochemical recurrence (BCR) risk model was created based on pretest prostate specific antigen (PSA) and restaging prostate specific membrane antigen (PSMA) PET/CT. Both pretest PSA and PSMA PET/CT were found to be important for the overall survival (OS) of BCR patients. Treatment center, International Society of Urologic Pathology (ISUP) grade, pretest PSA threshold, and the grouping of positive sites on the restaging PSMA PET/CT were significant predictors of OS.
Article
Nutrition & Dietetics
Daniel Keizman, Moshe Frenkel, Avivit Peer, Igal Kushnir, Eli Rosenbaum, David Sarid, Ilan Leibovitch, Roy Mano, Ofer Yossepowitch, David Margel, Ido Wolf, Ravit Geva, Hadas Dresler, Keren Rouvinov, Noa Rapoport, Isaac Eliaz
Summary: The study showed that in non-metastatic biochemically relapsed prostate cancer patients, treatment with P-MCP significantly reduced PSA progression rates, improved PSA doubling time, and had no severe toxic effects.
Article
Urology & Nephrology
Rashid K. K. Sayyid, Rui Bernardino, Zizo Al-Daqqaq, Raj Tiwari, Jessica Cockburn, Shagana Vijayakanthan, Ricardo Leao, Yazan Qaoud, Mohamad Baker Berjaoui, Ur Metser, Alejandro Berlin, Neil E. E. Fleshner
Summary: This study found that 11.3% of patients with biochemically recurrent prostate cancer had mesorectal lymph node (MLN) metastases on PSMA-PET/CT. The presence of pT3b disease was significantly associated with increased odds of MLN metastasis. These findings suggest alternate drainage routes for prostate cancer cells.
Article
Nutrition & Dietetics
Daniel Keizman, Moshe Frenkel, Avivit Peer, Eli Rosenbaum, David Sarid, Ilan Leibovitch, Roy Mano, Ofer Yossepowitch, Ido Wolf, Ravit Geva, David Margel, Keren Rouvinov, Anat Stern, Hadas Dresler, Igal Kushnir, Isaac Eliaz
Summary: The study shows that P-MCP may have long-term durable efficacy and is safe for patients with non-metastatic biochemically relapsed prostate cancer (BRPC-M0). This provides hope for the treatment of BRPC-M0 patients.
Article
Radiology, Nuclear Medicine & Medical Imaging
Lucia Baratto, Hong Song, Heying Duan, Negin Hatami, Hilary P. Bagshaw, Mark Buyyounouski, Steven Hancock, Sumit Shah, Sandy Srinivas, Patrick Swift, Farshad Moradi, Guido Davidzon, Andrei Iagaru
Summary: The novel radiopharmaceutical Ga-68-RM2 shows promising results in the diagnosis of biochemical recurrence of prostate cancer compared to Ga-68-PSMA11 and F-18-DCFPyL. Larger studies are needed to determine the complementary use of these radiopharmaceuticals for personalized medicine.
JOURNAL OF NUCLEAR MEDICINE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Monica Abghari-Gerst, Wesley R. Armstrong, Kathleen Nguyen, Jeremie Calais, Johannes Czernin, David Lin, Namasvi Jariwala, Melissa Rodnick, Thomas A. Hope, Jason Hearn, Jeffrey S. Montgomery, Ajjai Alva, Zachery R. Reichert, Daniel E. Spratt, Timothy D. Johnson, Peter J. H. Scott, Morand Piert
Summary: This study prospectively investigated the performance of prostate adenocarcinoma in patients with elevated PSA levels after initial therapy. The results showed that 68GaPSMA-11 PET can accurately detect the presence and disease burden of prostate cancer in patients who have undergone different treatments.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
H. Briody, M. Sheehan, M. Hanley, B. O'Neil, R. Dunne, M. J. Lee, M. M. Morrin
Summary: This study assessed the utility of magnetic resonance imaging (MRI) in addition to conventional imaging techniques for investigating biochemical recurrence (BCR) postprostatectomy. The results showed that MRI findings can be used to predict the additive value of computed tomography (CT) and nuclear medicine (NM) bone scintigraphy, leading to a more appropriate use of resources.
CLINICAL RADIOLOGY
(2023)
Article
Oncology
Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frederic Pouliot, David Josephson, Jeffrey Y. C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel
Summary: F-18-DCFPyL-PET/CT demonstrated good localization performance in patients with BCR, providing meaningful and actionable information that led to a change in management for 63.9% of patients.
CLINICAL CANCER RESEARCH
(2021)
Article
Medicine, Research & Experimental
Eric Zhuang, Edward Uchio, Michael Lilly, Xiaolin Zi, John P. Fruehauf
Summary: Docetaxel plus lycopene therapy showed effectiveness in advanced castrate resistant adenocarcinoma of prostate, with a 76.9% PSA response rate and a median survival of 35.1 months, indicating the potential value of this combination therapy.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Gary A. Ulaner, Beth Thomsen, Jeffrey Bassett, Robert Torrey, Craig Cox, Kevin Lin, Trushar Patel, Tust Techasith, Audrey Mauguen, Steven P. Rowe, Liza Lindenberg, Esther Mena, Peter Choyke, Jeffrey Yoshida
Summary: The positive predictive value (PPV) of DCFPyL PET/CT was evaluated for suspected distant metastases and recurrence sites in newly diagnosed high-risk and biochemically recurrent (BCR) prostate cancer. The results showed a PPV of 74% in newly diagnosed prostate cancer and 89% in BCR prostate cancer. However, false-positive findings in ribs and pelvic bones should be considered.
Article
Oncology
P. A. Glemser, L. T. Rotkopf, C. H. Ziener, B. Beuthien-Baumann, V Weru, A. Kopp-Schneider, H. P. Schlemmer, A. Dimitrakopoulou-Strauss, C. Sachpekidis
Summary: [Ga-68]PSMA-11 PET-CT and PET-MRI provide equally good detection rates for prostate cancer recurrence, both outperforming stand-alone MRI. PET-MRI is particularly efficient in detecting local recurrences in the prostate bed, while there were no significant differences in lesion detection rate between PET-CT and PET-MRI. The probability of a positive scan significantly increased with increasing PSA levels for all imaging modalities.
Article
Oncology
Bo Li, Lili Duan, Jingqi Shi, Yunyun Han, Wei Wei, Xiaoliang Cheng, Yong Cao, Akeban Kader, Degang Ding, Xinyu Wu, Yongju Gao
Summary: This study investigated the diagnostic yield of 99mTc-HYNIC-PSMA SPECT/CT in patients with biochemically recurrent prostate cancer after radical prostatectomy. The results showed a high detection rate of 99mTc-HYNIC-PSMA SPECT/CT for prostate cancer, which was positively correlated with PSA levels and ADT.
FRONTIERS IN ONCOLOGY
(2022)
Review
Urology & Nephrology
Laura Bukavina, Amy N. Luckenbaugh, Michael S. Hofman, Tom Hope, Sophia C. Kamran, Declan G. Murphy, Kosj Yamoah, Piet Ost
Summary: This article summarizes the available data and recommendations on the use of PSMA in newly diagnosed and recurrent prostate cancer. PSMA-targeted imaging shows superior performance in primary and recurrent prostate cancer compared to conventional imaging, but with some limitations. Pretreatment 68Ga-PSMA PET/CT provides more accurate staging and detects unknown metastatic lesions. PSMA PET has greater sensitivity and specificity in detecting recurrence in biochemically recurrent prostate cancer, potentially identifying a major proportion of occult disease.
